Related references
Note: Only part of the references are listed.Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder
Laura Brandt et al.
DRUG AND ALCOHOL DEPENDENCE (2020)
Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys
E. Andrew Townsend et al.
DRUG AND ALCOHOL DEPENDENCE (2020)
A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder
Mohammad Sibai et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2020)
Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018
Nana Wilson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured to cohort
Jake R. Morgan et al.
DRUG AND ALCOHOL DEPENDENCE (2019)
Overdose Deaths Involving Fentanyl and Fentanyl Analogs - New York City, 2000-2017
Cody Colon-Berezin et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Medications for management of opioid use disorder
Jennifer L. Koehl et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2019)
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial
Adam Bisaga et al.
DRUG AND ALCOHOL DEPENDENCE (2018)
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Joshua D. Lee et al.
LANCET (2018)
Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys
Stephen J. Kohut et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population
Jake R. Morgan et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2018)
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
Luis Sordo et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
Luis Sordo et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine
Maria Sullivan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats
Harshini Neelakantan et al.
ACS CHEMICAL NEUROSCIENCE (2017)
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment
Christopher M. Jones et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2015)
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone
Adam Bisaga et al.
DRUG AND ALCOHOL DEPENDENCE (2015)
Activation of serotonin 5-HT2C receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice
Xian Wu et al.
NEUROSCIENCE LETTERS (2015)
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial
Yih-Ing Hser et al.
ADDICTION (2014)
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: A very low dose naltrexone and buprenorphine open label trial
Paolo Mannelli et al.
DRUG AND ALCOHOL DEPENDENCE (2014)
Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction
Kathryn A. Cunningham et al.
NEUROPHARMACOLOGY (2014)
A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence
Adam Bisaga et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2014)
Assessment of riboflavin as a tracer substance: Comparison of a qualitative to a quantitative method of riboflavin measurement
Abigail J. Herron et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5-HT2C) Receptor Agonist, in Recreational Polydrug Users
M. J. Shram et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Blocked Randomization with Randomly Selected Block Sizes
Jimmy Efird
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2011)
The COMBINE SAFTEE: A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field
BA Johnson et al.
JOURNAL OF STUDIES ON ALCOHOL (2005)
The clinical opiate withdrawal scale (COWS)
DR Wesson et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2003)
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial
J Kakko et al.
LANCET (2003)
Behavioral naltrexone therapy: an integrated treatment for opiate dependence
JL Rothenberg et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2002)
Share Paper
